ContextMore than 50 million US adults take aspirin regularly for long-term prevention of
cardiovascular disease, typically either 81 mg/d or 325 mg/d. Controversy remains regarding …

Studies focused on patient responsiveness to antiplatelet therapies, particularly aspirin and
clopidogrel, have increased in recent years. However, the relations of in vivo platelet …

The content of these European Society of Cardiology (ESC) Guidelines has been published
for personal and educational use only. No commercial use is authorized. No part of the ESC …

Aims We sought to compare the results obtained from six major platelet function tests in the
assessment of the prevalence of aspirin resistance in patients with stable coronary artery …

Background The risk of recurrence of cardiovascular events among patients using aspirin
(acetylsalicylic acid) for secondary prevention of such events remains high. Persistent …

Background—The antiplatelet effect of aspirin is attributed to platelet cyclooxygenase-1
inhibition. Controversy exists on the prevalence of platelet resistance to aspirin in patients …

The platelet, once thought to be solely involved in clot formation, is now known to be a key
mediator in various others processes such as inflammation, thrombosis, and atherosclerosis …

BACKGROUND: The absolute risk of recurrences among patients using aspirin for
prevention of cardiovascular events remains high. Persistent platelet reactivity despite …

Aspirin is effective in the prevention of cardiovascular events in high-risk patients. The
primary established effect of aspirin on hemostasis is to impair platelet aggregation via …

Background: The mechanisms for the variability in antiplatelet effects of aspirin are unclear.
Immature (reticulated) platelets may modulate the antiplatelet effects of aspirin through …